What is the significance of Anti-Müllerian Hormone (AMH) levels in a female patient of reproductive age with endometriosis, particularly in relation to ovarian reserve and fertility?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 6, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

AMH Levels in Endometriosis

Women with endometriosis have significantly reduced AMH levels compared to those without the disease, with the most severe reductions occurring in patients with ovarian endometriomas and those who have undergone prior endometrioma surgery. 1, 2, 3

Impact of Endometriosis on Ovarian Reserve

Disease-Related AMH Reduction

  • Women with stage III-IV endometriosis demonstrate mean AMH levels of 0.97 ± 0.59 ng/ml compared to 1.72 ± 0.63 ng/ml in fertile controls (p=0.001), representing a 44% reduction. 2 This represents incipient ovarian failure and early ovarian depletion in young women.

  • Laparoscopically-confirmed endometriosis is associated with 29.6% lower AMH levels (95% CI: -45.4%, -9.2%) compared to women without endometriosis. 3 This reduction is more pronounced in women with BMI ≥25 kg/m² (44% reduction) versus BMI <25 kg/m² (19.8% reduction). 3

  • The detrimental effect of endometriosis on AMH is age-dependent and becomes statistically significant only in women aged 35 years or older, suggesting an age-enhancement effect. 4

Phenotype-Specific Effects

Ovarian endometriomas (OMAs) are the primary driver of reduced AMH levels in endometriosis patients. 1 The evidence shows:

  • OMA is linked to reduced AMH values and a higher AMH decline rate over time, even before surgical intervention. 1

  • Superficial peritoneal endometriosis has little to no impact on AMH levels. 1

  • Deep infiltrating endometriosis reduces AMH levels, though the mechanism may involve extra-ovarian factors beyond simple follicular depletion. 1

Surgical Impact on AMH

Prior endometrioma surgery is the strongest predictor of diminished AMH levels in endometriosis patients, independent of current disease presence. 5

  • Women with previous OMA surgery have significantly lower AMH levels regardless of whether endometriomas are currently present (OR = 3.0 for AMH <1 ng/ml, 95% CI: 1.4-6.41, p=0.01). 5

  • OMA cystectomy causes further AMH reduction beyond the disease effect itself, though AMH tends to recover partially postoperatively. 1

  • Non-excisional surgery for OMA (drainage/ablation) spares more ovarian parenchyma and causes smaller AMH declines than cystectomy, though at least temporary reduction still occurs. 1

  • Non-thermal hemostasis methods following cystectomy are superior to thermal methods in terms of preserving AMH levels. 1

Clinical Utility of AMH Assessment

Ovarian Reserve Evaluation

AMH correlates well with antral follicle count (AFC) and is superior to age, basal FSH, estradiol, and inhibin B for assessing ovarian reserve in healthy women. 6 Key advantages include:

  • AMH does not vary significantly by menstrual cycle day and is not affected by exogenous estrogen or progesterone use. 6

  • AMH is inversely correlated with age in women ≥25 years, making it clinically useful in this population. 7

  • Very low AMH levels (<0.7 ng/ml) indicate incipient ovarian insufficiency and represent the best endocrine marker for age-related decline in ovarian reserve. 8

Fertility Implications

Preoperative AMH levels in endometriosis patients are positively correlated with postoperative probability of pregnancy, particularly spontaneous conception, though not necessarily live birth rates. 1

  • Preoperative AMH is predictive of the risk of developing diminished ovarian reserve (DOR) after surgery. 1

  • Postoperative AMH levels and the rate of AMH decline at 1 year after OMA cystectomy predict fertility outcomes. 1

  • Women with severely low AMH (<0.7 ng/ml) face 91% increased odds of miscarriage (OR 1.91; 95% CI 1.40-2.60). 8

  • In women ≥35 years, low AMH confers 85% increased miscarriage risk (OR 1.85; 95% CI 1.35-2.52). 8

Clinical Management Algorithm

Assessment Strategy

  1. Measure AMH levels in all reproductive-age women with diagnosed or suspected endometriosis to establish baseline ovarian reserve. 6, 2

  2. Interpret AMH values in context of age (most reliable in women ≥25 years), BMI, and endometriosis phenotype. 7, 3, 4

  3. For women with irregular menses and low AMH, monitor for symptoms of premature ovarian insufficiency (POI). 8

  4. Obtain FSH and estradiol levels in women with suspected diminished ovarian reserve (AMH <1 ng/ml). 8

Surgical Decision-Making

The finding that OMA surgery—not endometriomas per se—causes the most significant AMH reduction should heavily influence surgical decision-making in women desiring future pregnancy. 5

  • Consider non-excisional approaches (drainage/ablation) over cystectomy when fertility preservation is paramount, particularly in women with already reduced AMH or bilateral disease. 1

  • If cystectomy is necessary, employ non-thermal hemostasis techniques to minimize ovarian damage. 1

Fertility Counseling

Counsel all women with endometriosis about their elevated risk of premature ovarian failure and the importance of not delaying childbearing. 6, 3

  • Women with AMH <1 ng/ml should pursue fertility evaluation and attempts promptly per American Society for Reproductive Medicine recommendations. 8

  • Discuss fertility preservation options (oocyte cryopreservation) before any planned endometrioma surgery, especially in women with low baseline AMH. 6

  • Refer to reproductive endocrinology for infertility evaluation and assisted reproduction consultation when AMH indicates diminished reserve. 6

Important Caveats

Different AMH assays yield varying results due to lack of international standardization, so interpret values within the specific laboratory's reference ranges. 8, 7

A reduction in AMH values following deep endometriosis surgery should not automatically be interpreted as decline in reproductive potential, as extra-ovarian factors may be involved. 1

AMH shows promise for predicting timing of menopause onset in endometriosis patients, which has implications for long-term cardiovascular disease risk. 6, 3

References

2
Research

Evaluation of serum anti-Mullerian hormone levels to assess the ovarian reserve in women with severe endometriosis.

European journal of obstetrics, gynecology, and reproductive biology, 2014

4
Research

Combined effects of age and endometriosis on ovarian reserve in women with infertility.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2023

6
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

7
Guideline

Ovarian Reserve Assessment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

8
Guideline

Implications of Low AMH Levels on Fertility

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Are Hydrochlorothiazide (HCTZ) 12.5mg and Chlorthalidone 12.5mg equivalent in terms of efficacy and potency for treating hypertension and edema?
Is atrial septal defect (ASD) sinus venosus a rare condition?
Does the absence of subjective symptoms in an elderly patient with hypertension, tachycardia, and unilateral pitting edema necessarily indicate a safer condition?
What is the best course of action for a patient with persistent tachycardia and hypertension, who attributes their symptoms to stress and sleep deprivation, in the absence of distal tibial pitting edema?
What could be causing the recent episodes of hypertension in an elderly female patient with a history of long QT syndrome, hypertension, controlled diabetes mellitus (DM) with metformin, hyperlipidemia controlled with atorvastatin, taking estrodiol, metoprolol, with an implanted implantable cardioverter-defibrillator (ICD), recent weight loss, sarcopenia, controlled depression with Effexor (venlafaxine), and stable sarcoidosis?
Is it appropriate to admit a 70-year-old female patient with a history of hypertension and sinus tachycardia to a Physical Medicine and Rehabilitation (PM&R) hospital with no access to laboratory services or specialist consultation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question